443 related articles for article (PubMed ID: 25829347)
1. PLASMA CONCENTRATIONS OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN RETINOPATHY OF PREMATURITY AFTER INTRAVITREAL BEVACIZUMAB INJECTION.
Hong YR; Kim YH; Kim SY; Nam GY; Cheon HJ; Lee SJ
Retina; 2015 Sep; 35(9):1772-7. PubMed ID: 25829347
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity.
Wu WC; Lien R; Liao PJ; Wang NK; Chen YP; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC
JAMA Ophthalmol; 2015 Apr; 133(4):391-7. PubMed ID: 25569026
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity.
Kong L; Bhatt AR; Demny AB; Coats DK; Li A; Rahman EZ; Smith OE; Steinkuller PG
Invest Ophthalmol Vis Sci; 2015 Jan; 56(2):956-61. PubMed ID: 25613938
[TBL] [Abstract][Full Text] [Related]
4. Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab.
Matsuyama K; Ogata N; Matsuoka M; Wada M; Takahashi K; Nishimura T
Br J Ophthalmol; 2010 Sep; 94(9):1215-8. PubMed ID: 20538658
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab.
Zhou Y; Jiang Y; Bai Y; Wen J; Chen L
Graefes Arch Clin Exp Ophthalmol; 2016 Jan; 254(1):31-6. PubMed ID: 25851862
[TBL] [Abstract][Full Text] [Related]
6. Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab.
Nonobe NI; Kachi S; Kondo M; Takai Y; Takemoto K; Nakayama A; Hayakawa M; Terasaki H
Retina; 2009 May; 29(5):579-85. PubMed ID: 19430279
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Plasma Cytokine Profile Changes in Bevacizumab-Treated Retinopathy of Prematurity Infants.
Kong L; Demny AB; Sajjad A; Bhatt AR; Devaraj S
Invest Ophthalmol Vis Sci; 2016 Apr; 57(4):1649-54. PubMed ID: 27054517
[TBL] [Abstract][Full Text] [Related]
8. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity.
Sato T; Wada K; Arahori H; Kuno N; Imoto K; Iwahashi-Shima C; Kusaka S
Am J Ophthalmol; 2012 Feb; 153(2):327-333.e1. PubMed ID: 21930258
[TBL] [Abstract][Full Text] [Related]
9. Plasma Levels of Bevacizumab and Vascular Endothelial Growth Factor After Low-Dose Bevacizumab Treatment for Retinopathy of Prematurity in Infants.
; Hartnett ME; Wallace DK; Dean TW; Li Z; Boente CS; Dosunmu EO; Freedman SF; Golden RP; Kong L; Prakalapakorn SG; Repka MX; Smith LE; Wang H; Kraker RT; Cotter SA; Holmes JM
JAMA Ophthalmol; 2022 Apr; 140(4):337-344. PubMed ID: 35446359
[TBL] [Abstract][Full Text] [Related]
10. Reactivation of retinopathy of prematurity after ranibizumab treatment.
Wong RK; Hubschman S; Tsui I
Retina; 2015 Apr; 35(4):675-80. PubMed ID: 25768252
[TBL] [Abstract][Full Text] [Related]
11. Short-term effect of intravitreal ranibizumab on intraocular concentrations of vascular endothelial growth factor-A and pigment epithelium-derived factor in neovascular glaucoma.
Wang JW; Zhou MW; Zhang X; Huang WB; Gao XB; Wang W; Chen S; Zhang XY; Ding XY; Jonas JB
Clin Exp Ophthalmol; 2015 Jul; 43(5):415-21. PubMed ID: 25488632
[TBL] [Abstract][Full Text] [Related]
12. Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity.
Huang CY; Lien R; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
Graefes Arch Clin Exp Ophthalmol; 2018 Mar; 256(3):479-487. PubMed ID: 29290015
[TBL] [Abstract][Full Text] [Related]
13. SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER BEVACIZUMAB OR RANIBIZUMAB TREATMENT FOR RETINOPATHY OF PREMATURITY.
Wu WC; Shih CP; Lien R; Wang NK; Chen YP; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC
Retina; 2017 Apr; 37(4):694-701. PubMed ID: 27467377
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity.
Karkhaneh R; Khodabande A; Riazi-Eafahani M; Roohipoor R; Ghassemi F; Imani M; Dastjani Farahani A; Ebrahimi Adib N; Torabi H
Acta Ophthalmol; 2016 Sep; 94(6):e417-20. PubMed ID: 27009449
[TBL] [Abstract][Full Text] [Related]
15. Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity.
Kim J; Kim SJ; Chang YS; Park WS
Retina; 2014 Jan; 34(1):77-82. PubMed ID: 23807184
[TBL] [Abstract][Full Text] [Related]
16. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity.
Sato T; Kusaka S; Shimojo H; Fujikado T
Ophthalmology; 2009 Sep; 116(9):1599-603. PubMed ID: 19371954
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal low-dosage bevacizumab for retinopathy of prematurity.
Harder BC; von Baltz S; Jonas JB; Schlichtenbrede FC
Acta Ophthalmol; 2014 Sep; 92(6):577-81. PubMed ID: 24020921
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal Bevacizumab for Zone II Retinopathy of Prematurity.
Larrañaga-Fragoso P; Peralta J; Bravo-Ljubetic L; Pastora N; Abelairas-Gómez J
J Pediatr Ophthalmol Strabismus; 2016 Nov; 53(6):375-382. PubMed ID: 27537247
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab following laser therapy for severe retinopathy of prematurity.
Erol N; Gürsoy H; Sahin A; Basmak H
J Pediatr Ophthalmol Strabismus; 2010 Aug; 47 Online():e1-4. PubMed ID: 21158371
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity - 27 month follow-up results from Turkey.
Yetik H; Gunay M; Sirop S; Salihoglu Z
Graefes Arch Clin Exp Ophthalmol; 2015 Oct; 253(10):1677-83. PubMed ID: 25501298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
